Internal Medicine, Hematology & Oncology · Cooperstown, NY
NPI
1790986081
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
1 Atwell Rd
Cooperstown, NY, 13326
Phone (607) 547-3336
Groups this clinician bills Medicare through
Medicare paid, 2024
$56K
1,017 services
Medicare patients, 2024
272
Average age 74
Drug cost, 2024
$4.7M
1,677 prescriptions
Company payments, 2025
$121K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anush Patel was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 356 times for 154 patients. In total Anush Patel billed 1,017 services in 17 codes, and Medicare paid $56K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-08-09.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 356 | 154 | $12.34 | $4,393 |
| 99215 Office E&M - Established | Facility | 261 | 113 | $99.02 | $26K |
| 99214 Office E&M - Established | Facility | 209 | 135 | $68.11 | $14K |
| 99213 Office E&M - Established | Facility | 92 | 82 | $45.68 | $4,203 |
| 99205 Office E&M - New | Facility | 25 | 25 | $123.30 | $3,083 |
By year: 2022 $66K for 861 services; 2023 $56K for 813 services; 2024 $56K for 1,017 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anush Patel prescribed most often to Medicare patients was Warfarin Sodium, with 174 prescriptions and refills. In total Anush Patel wrote 1,677 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Warfarin Sodium Generic | 174 | 474 | 72 | $1,806 |
| Letrozole Generic | 118 | 320 | 35 | $2,844 |
| Prochlorperazine Maleate Generic | 71 | 75 | 54 | $695 |
| Prednisone Generic | 71 | 88 | 23 | $351 |
| Ondansetron Odt Ondansetron | 70 | 70 | 43 | $1,009 |
| Eliquis Apixaban | 65 | 89 | 17 | $48K |
| Dexamethasone Generic | 63 | 82 | 33 | $1,178 |
| Valacyclovir Valacyclovir Hcl | 57 | 71 | 14 | $1,388 |
| Lenalidomide Generic | 53 | 53 | Under 11 | $756K |
| Anastrozole Generic | 49 | 93 | 13 | $756 |
| Hydroxyurea Generic | 40 | 114 | 13 | $1,289 |
| Tagrisso Osimertinib Mesylate | 40 | 40 | Under 11 | $664K |
| Enoxaparin Sodium Generic | 38 | 38 | 30 | $5,784 |
| Abiraterone Acetate Generic | 35 | 35 | Under 11 | $64K |
| Potassium Chloride Generic | 31 | 35 | 11 | $365 |
Brand drugs: 345 claims; generic drugs: 1,332 claims; opioid claims: 92.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anush Patel $121K ($121K in general payments such as food, travel and fees) from 13 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $71K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 39 | $71K |
| Regeneron Healthcare Solutions, Inc. REGN | 15 | $27K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $11K |
| Daiichi Sankyo Inc. 4568.T | 6 | $6,785 |
| E.R. Squibb & Sons, L.L.C. BMY | 8 | $4,690 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $207 |
| Janssen Biotech, Inc. JNJ | 1 | $77.76 |
| PharmaEssentia USA Corporation 6446.TW | 1 | $28.24 |
| Iovance Biotherapeutics, Inc. IOVA | 1 | $24.44 |
| Novocure Inc. NVCR | 1 | $22.16 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.